三期 RTS, S/AS01 疟疾疫苗试验的疗效：需要替代的研发计划。
Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
机构信息
a Pediatric Infectious Disease Research Center , Tehran University of Medical Science , Tehran , Iran.
b Center for Research of Endemic Parasites of Iran (CREPI) , Tehran University of Medical Sciences , Tehran , Iran.
出版信息
Hum Vaccin Immunother. 2017 Sep 2;13(9):2098-2101. doi: 10.1080/21645515.2017.1295906. Epub 2017 Mar 8.
Abstract
Although vaccines would be the ideal tool for control, prevention, elimination, and eradication of many infectious diseases, developing of parasites vaccines such as malaria vaccine is very complex. The most advanced malaria vaccine candidate RTS,S, a pre-erythrocytic vaccine, has been recommended for licensure by EMEA. The results of this phase III trial suggest that this candidate malaria vaccine has relatively little efficacy, and the vaccine apparently will not meet the goal of malaria eradication by itself. Since there are many vaccine candidates in the pipeline that are being evaluated in vaccine trials, further study on using of alternative parasite targets and vaccination strategies are highly recommended.
摘要
尽管疫苗是控制、预防、消除和消灭许多传染病的理想工具，但寄生虫疫苗（如疟疾疫苗）的开发非常复杂。最先进的疟疾疫苗候选物 RTS,S，一种红细胞前期疫苗，已被 EMEA 推荐用于许可。这项 III 期试验的结果表明，这种候选疟疾疫苗的疗效相对较低，而且该疫苗显然无法独自实现消除疟疾的目标。由于有许多候选疫苗正在疫苗试验中进行评估，因此强烈建议进一步研究替代寄生虫靶标和疫苗接种策略的使用。
相似文献
1
Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.三期 RTS, S/AS01 疟疾疫苗试验的疗效：需要替代的研发计划。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2098-2101. doi: 10.1080/21645515.2017.1295906. Epub 2017 Mar 8.
2
Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.RTS,S/AS疟疾疫苗的临床开发：对I-III期临床试验的系统评价
Future Microbiol. 2015;10(10):1553-78. doi: 10.2217/fmb.15.90. Epub 2015 Oct 6.
3
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.RTS,S/AS01E 候选疟疾疫苗与扩大免疫规划疫苗联合接种的安全性和有效性：一项随机、开放标签、2 期临床试验的 19 个月随访。
Lancet Infect Dis. 2011 Oct;11(10):741-9. doi: 10.1016/S1473-3099(11)70100-1. Epub 2011 Jul 22.
4
The march toward malaria vaccines.迈向疟疾疫苗的征程。
Vaccine. 2015 Nov 27;33 Suppl 4(Suppl 4):D13-23. doi: 10.1016/j.vaccine.2015.07.091. Epub 2015 Aug 29.
5
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.RTS,S/AS01E 疟疾疫苗候选者在 5 至 17 个月大的肯尼亚和坦桑尼亚儿童中的安全性。
PLoS One. 2010 Nov 29;5(11):e14090. doi: 10.1371/journal.pone.0014090.
6
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.在非洲不同传播环境下评估 RTS,S/AS01 疟疾疫苗在儿童中的疗效的 III 期多中心试验设计。
Malar J. 2011 Aug 4;10:224. doi: 10.1186/1475-2875-10-224.
7
The Advanced Development Pathway of the RTS,S/AS01 Vaccine.RTS,S/AS01疫苗的先进研发途径。
Methods Mol Biol. 2019;2013:177-187. doi: 10.1007/978-1-4939-9550-9_13.
8
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.RTS,S/AS01 疟疾疫苗在婴幼儿中的安全性特征：撒哈拉以南非洲地区 III 期随机对照试验的补充数据。
Hum Vaccin Immunother. 2019;15(10):2386-2398. doi: 10.1080/21645515.2019.1586040. Epub 2019 Apr 23.
9
Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.在未感染过疟疾的健康成年人中，对与AS02佐剂系统配制的联合红细胞前期疫苗抗原RTS,S和TRAP的安全性、免疫原性和有效性进行的1期和2期序贯随机对照试验。
Vaccine. 2014 Nov 20;32(49):6683-91. doi: 10.1016/j.vaccine.2014.06.033. Epub 2014 Jun 18.
10
[The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].疟疾候选疫苗RTS,S/AS正在进行三期临床试验。
Ann Pharm Fr. 2010 Nov;68(6):370-9. doi: 10.1016/j.pharma.2010.07.002. Epub 2010 Oct 13.
引用本文的文献
1
Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South.疟疾与 mRNA 疫苗：一种可能拯救全球南方最相关传染病之一的方法。
Acta Parasitol. 2023 Dec;68(4):916-928. doi: 10.1007/s11686-023-00712-y. Epub 2023 Oct 12.
2
Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria.脑内皮细胞上离散的 I 类分子差异调节实验性脑疟疾中的神经病理学。
Brain. 2024 Feb 1;147(2):566-589. doi: 10.1093/brain/awad319.
3
Analysis of gene expression profiles to study malaria vaccine dose efficacy and immune response modulation.分析基因表达谱以研究疟疾疫苗剂量疗效和免疫反应调节。
Genomics Inform. 2022 Sep;20(3):e32. doi: 10.5808/gi.22049. Epub 2022 Sep 30.
4
Nanoincorporation of Plumbagin in Micelles Increase Its in Vivo Anti-Plasmodial Properties.白花丹醌纳米胶束的制备增强其体内抗疟特性。
Iran J Parasitol. 2022 Apr-Jun;17(2):202-213. doi: 10.18502/ijpa.v17i2.9538.
5
Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model.工程化 DNA 编码的针对恶性疟原虫环子孢子蛋白的单克隆抗体在小鼠疟疾攻毒模型中提供单次剂量保护。
Sci Rep. 2022 Aug 22;12(1):14313. doi: 10.1038/s41598-022-18375-6.
6
Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages.脂质体共展示 CSP 和 Pfs230 疫苗，针对疟原虫两个分化阶段。
Commun Biol. 2022 Aug 1;5(1):773. doi: 10.1038/s42003-022-03688-z.
7
[Malarial antigens in the era of mRNA vaccines].[mRNA疫苗时代的疟疾抗原]
Monatsschr Kinderheilkd. 2022;170(9):828-838. doi: 10.1007/s00112-022-01554-0. Epub 2022 Jul 14.
8
Breadth of Antibodies to Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.抗体对变异表面抗原的广谱性与在一项人体疟疾感染控制研究中的免疫有关。
Front Immunol. 2022 May 30;13:894770. doi: 10.3389/fimmu.2022.894770. eCollection 2022.
9
Pediatric Participant Retention Rates in a Longitudinal Malaria Immunology Study.一项纵向疟疾免疫学研究中的儿科参与者保留率
Am J Trop Med Hyg. 2022 Apr 18;106(6):1629-36. doi: 10.4269/ajtmh.21-1052.
10
Liposomes for malaria management: the evolution from 1980 to 2020.脂质体用于疟疾管理：1980 年至 2020 年的发展历程。
Malar J. 2021 Jul 27;20(1):327. doi: 10.1186/s12936-021-03858-0.
本文引用的文献
1
Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.评估从多个可溶性表达平台表达的Pfs25作为传播阻断疫苗候选物的情况。
Malar J. 2016 Aug 11;15(1):405. doi: 10.1186/s12936-016-1464-6.
2
RTS,S Malaria Vaccine and Increased Mortality in Girls.RTS,S疟疾疫苗与女童死亡率上升
mBio. 2016 Apr 26;7(2):e00514-16. doi: 10.1128/mBio.00514-16.
3
The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan.RTS,S/AS01疟疾疫苗的未来：一项替代发展计划。
PLoS Med. 2016 Apr 12;13(4):e1001994. doi: 10.1371/journal.pmed.1001994. eCollection 2016 Apr.
4
Status of vaccine research and development of vaccines for malaria.疟疾疫苗的研发现状
Vaccine. 2016 Jun 3;34(26):2915-2920. doi: 10.1016/j.vaccine.2015.12.074. Epub 2016 Mar 15.
5
The March Toward Malaria Vaccines.迈向疟疾疫苗的征程
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S319-33. doi: 10.1016/j.amepre.2015.09.011.
6
RTS,S/AS01 malaria vaccine and child mortality.RTS,S/AS01疟疾疫苗与儿童死亡率
Lancet. 2015 Oct 31;386(10005):1736. doi: 10.1016/S0140-6736(15)00694-7.
7
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.RTS,S/AS01疟疾疫苗在非洲婴幼儿中接种或不接种加强剂量的疗效和安全性：一项3期个体随机对照试验的最终结果
Lancet. 2015 Jul 4;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23.
8
Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.RTS,S/AS01疟疾疫苗接种后18个月的疗效和安全性：在11个非洲地点对儿童和幼儿进行的3期随机对照试验
PLoS Med. 2014 Jul 29;11(7):e1001685. doi: 10.1371/journal.pmed.1001685. eCollection 2014 Jul.
9
Malaria vaccine development and how external forces shape it: an overview.疟疾疫苗的研发及其受到的外部影响概述。
Int J Environ Res Public Health. 2014 Jun 30;11(7):6791-807. doi: 10.3390/ijerph110706791.
10
Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities.疫苗十年中的疟疾疫苗研发：突破、挑战和机遇。
Vaccine. 2013 Apr 18;31 Suppl 2:B233-43. doi: 10.1016/j.vaccine.2013.02.040.
Zotero 插件